Plain-English translation of NCT06303505 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial is testing a new drug called , which is designed to deliver cancer-fighting medicine directly to tumor cells. The medication works by targeting a specific protein (NaPi2b) that appears on ovarian and lung cancer cells. Researchers want to find the safest and most effective dose of this treatment for people whose cancers have stopped responding to standard therapies.
People with platinum-resistant ovarian cancer and certain advanced lung cancers often run out of treatment options that work. This medication offers a new approach by using an antibody to carry a powerful drug directly into cancer cells, which could reduce side effects and improve how well it works.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous injection (into a vein) every three weeks. The study has two phases: first, doctors will gradually increase doses in some patients to find the safest amount, and then compare different doses to pick the best one. You would continue receiving treatment as long as your cancer is responding and you are tolerating it well, with regular visits for blood tests, imaging scans, and health check-ups to monitor how you are doing.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States